Fuller & Thaler Asset Management Inc. Sells 396,733 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Fuller & Thaler Asset Management Inc. reduced its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 99.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,333 shares of the medical equipment provider's stock after selling 396,733 shares during the quarter. Fuller & Thaler Asset Management Inc.'s holdings in Lantheus were worth $119,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. GMT Capital Corp lifted its holdings in shares of Lantheus by 11.7% in the fourth quarter. GMT Capital Corp now owns 457,500 shares of the medical equipment provider's stock valued at $40,928,000 after purchasing an additional 47,800 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its position in shares of Lantheus by 40.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock valued at $135,025,000 after acquiring an additional 435,445 shares during the last quarter. Pinebridge Investments L.P. lifted its stake in Lantheus by 42.7% during the fourth quarter. Pinebridge Investments L.P. now owns 21,748 shares of the medical equipment provider's stock worth $1,946,000 after purchasing an additional 6,507 shares during the last quarter. Stifel Financial Corp increased its stake in Lantheus by 14.3% in the 4th quarter. Stifel Financial Corp now owns 38,497 shares of the medical equipment provider's stock worth $3,444,000 after purchasing an additional 4,816 shares during the period. Finally, Tower Research Capital LLC TRC boosted its position in Lantheus by 6.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,178 shares of the medical equipment provider's stock valued at $463,000 after buying an additional 309 shares during the period. Institutional investors own 99.06% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Truist Financial boosted their target price on Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. JMP Securities reaffirmed a "market outperform" rating and set a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. Finally, B. Riley decreased their price objective on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a report on Friday, March 21st. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $129.43.

Insider Activity at Lantheus

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at $11,445,207.20. The trade was a 8.07 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares of the company's stock, valued at $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 63,109 shares of company stock worth $6,016,046. 1.50% of the stock is owned by insiders.

Lantheus Stock Up 1.5 %

Lantheus stock traded up $1.58 during trading hours on Thursday, hitting $105.92. The stock had a trading volume of 979,467 shares, compared to its average volume of 951,309. The stock has a market capitalization of $7.25 billion, a P/E ratio of 17.62 and a beta of 0.20. The stock's 50-day moving average price is $98.78 and its 200-day moving average price is $95.20. Lantheus Holdings, Inc. has a 12-month low of $65.89 and a 12-month high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The business had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. On average, research analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.